Stoke Therapeutics (NASDAQ:STOK) Shares Down 5.6% – What’s Next?

Stoke Therapeutics, Inc. (NASDAQ:STOK)’s stock price fell 5.6% during mid-day trading on Tuesday . The stock traded as low as $10.00 and last traded at $9.98. 167,376 shares were traded during mid-day trading, a decline of 80% from the average session volume of 851,992 shares. The stock had previously closed at $10.57.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on STOK shares. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, January 8th. HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, January 8th. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Leerink Partners assumed coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 target price on the stock. Finally, Chardan Capital started coverage on shares of Stoke Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating and a $24.00 target price for the company. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Stoke Therapeutics has a consensus rating of “Buy” and a consensus price target of $21.29.

Stoke Therapeutics Price Performance

The stock has a market cap of $582.14 million, a price-to-earnings ratio of -5.23 and a beta of 0.95. The firm’s 50-day moving average is $11.08 and its 200 day moving average is $12.72.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. On average, sell-side analysts forecast that Stoke Therapeutics, Inc. will post -2.03 EPS for the current year.

Insider Activity

In other news, CEO Edward M. Md Kaye sold 6,170 shares of the stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $78,852.60. Following the completion of the sale, the chief executive officer now owns 68,671 shares in the company, valued at approximately $877,615.38. This trade represents a 8.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Barry Ticho sold 13,945 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $178,217.10. Following the transaction, the insider now directly owns 47,332 shares in the company, valued at $604,902.96. This trade represents a 22.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 62,849 shares of company stock valued at $809,421 in the last three months. Corporate insiders own 11.30% of the company’s stock.

Institutional Trading of Stoke Therapeutics

Several large investors have recently bought and sold shares of STOK. Rhumbline Advisers lifted its position in shares of Stoke Therapeutics by 6.0% during the fourth quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock worth $545,000 after purchasing an additional 2,787 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Stoke Therapeutics during the 4th quarter worth $124,000. Assenagon Asset Management S.A. lifted its holdings in Stoke Therapeutics by 2.9% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company’s stock worth $14,901,000 after buying an additional 38,446 shares in the last quarter. Exome Asset Management LLC purchased a new position in Stoke Therapeutics in the 3rd quarter valued at about $2,170,000. Finally, Barclays PLC grew its stake in shares of Stoke Therapeutics by 145.3% during the third quarter. Barclays PLC now owns 79,740 shares of the company’s stock valued at $980,000 after acquiring an additional 47,239 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.